Filter By Category
Archives
Share on -
AMELPARIB
Generic Name: AMELPARIB
ABSTRACT -
Amelparib (JPI-289) is an investigational small-molecule inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1). It has been studied for neuroprotection in acute ischemic stroke and related ischemia-reperfusion injury research, where excessive PARP-1 activation after DNA damage can deplete cellular NAD+/ATP and contribute to parthanatos and inflammatory injury. It is not an approved routine stroke treatment.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- No approved routine dosing regimen is established.
- Clinical-trial administration is protocol-specific and must not delay approved acute-stroke care.
- Route, dose, timing after symptom onset, and monitoring depend on trial inclusion criteria and safety rules.
SIDE EFFECTS–
Possible side effects and safety concerns include:
- Human safety data are limited.
- Headache, dizziness, nausea, or infusion/injection-site symptoms may occur depending on formulation.
- Laboratory abnormalities may occur and require protocol monitoring.
- PARP-inhibitor class concerns include fatigue, gastrointestinal effects, haematologic abnormalities, and possible hepatic effects.
ALLRGIC REACTIONS–
Hypersensitivity to Amelparib or related compounds/products may occur. Symptoms may include:
- Rash
- Urticaria
- Facial swelling
- Wheezing or breathing difficulty
- Severe hypersensitivity reaction
Important: Patients who develop an allergic reaction to Amelparib should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS–
Amelparib may interact with certain medicines, vaccines, protocols, or clinical conditions. Caution is needed with:
- Other investigational neuroprotective agents may confound safety or efficacy assessment.
- Myelosuppressive or hepatotoxic medicines may increase monitoring needs.
- Anticoagulants and antiplatelets are common in stroke care and require protocol-specific review.
- CYP or transporter interactions are not fully characterized.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Use only in centers capable of standard acute-stroke evaluation and management.
- Do not replace reperfusion therapy, antithrombotic therapy, rehabilitation, or other guideline-directed care.
- Monitor neurological status, vital signs, blood counts, liver function, and renal function as specified by protocol.
- Pregnancy and lactation safety are not established.
WARNINGS –
- Investigational drug: do not use outside an authorized protocol.
- Delays in established stroke treatment can worsen disability or mortality.
- Unknown long-term safety and interaction profile.
- Keep out of reach of children.
Share on -
. Developed by